Redeye comments on Evolution’s Q1-results which were somewhat weaker than expected, driven by soft r...
Egetis delivered sales along expectations and more importantly, the German launch is underway follow...
'25e sales cut by 5%, three system deliveries for '25e (prev.
Redeye updates its view on M.O.B.A. Network following the Q1 2025 report.
Redeye updates its estimates and valuation for Tradedoubler following the Q1 2025 report.
Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report.
Q1: Sales 4% below, EBITDA NOK 10m vs ABGSCe of NOK 4m Lower target range likely EBIT estimates larg...
Order momentum from Q4 continues, up 18% y-o-y, de-risking '25e Stronger margin in both segments, bu...
Q1: +29% org. sales growth, SEK 9m adj. EBITA improvement '25e-'27e adj.
Acceleration across segments - organic momentum improved Another (self-funded) Thebalux-size acquisi...
Redeye retains its positive view of Sdiptech following a stable Q1 report.
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Redeye was hoping for a bit more in Q1, despite adverse market conditions related to macroeconomic u...
Nettoomsättningen kom in åt det svagare hållet men resultatet förbättrades, drivet av ökade licensin...
Marknadens oro över hur Trumps handelstullar skulle komma att påverka verksamheten kom på skam.
Orders +7%, sales -1%, adj. EBITA +28% vs. our estimates Key takeaway is the continued order strengt...
Relais announced it will acquire Team Verksted Holding AS from Vy Buss AS, making it the largest ope...
Sales in line with ABGSCe, ARR slightly below Limited, downward consensus estimate revisions Highlig...
Sales +11% y-o-y, in line with ABGSCe 5% adj. EBIT beat, 9% adj.
Adj. EBITA -12% vs cons, but organic growth better Est's down 3-4%, but better growth outlook mainta...